Sirovich B E, Gottlieb D J, Fisher E S
White River Junction VA Hospital, Vermont, and Dartmouth Medical School, Hanover, New Hampshire, USA.
J Med Screen. 2003;10(4):189-95. doi: 10.1258/096914103771773294.
Although cervical cancer is an unusual cause of death among women 65 and older, most elderly women in the US report continuing to undergo periodic Pap smear screening.
To describe the incidence of Pap smears and downstream testing among elderly women.
Claims-based analysis of female Medicare enrollees age 65 and older.
Using three years of Medicare Part B 5% Files (1995-1997), we differentiated between women undergoing screening Pap smears and those undergoing Pap smears for surveillance of previous abnormalities or Pap smear follow-up. We determined the proportion of elderly women undergoing Pap smear testing and rates of downstream testing and procedures after an initial Pap smear.
Four million female Medicare beneficiaries over 65 years underwent Pap smear testing between 1995 and 1997, representing 25% of the eligible population. After adjusting for underbilling for Pap smears under Medicare, 43% of women over 65 are estimated to have undergone Pap smear testing during the 3-year period. The large majority (90%) of Pap smears were for screening, while 10% were done for surveillance or follow-up. For every 1000 women with a screening Pap smear, 39 had at least one downstream intervention within eight months of the initial Pap smear, including seven women who underwent colposcopy and two women who had other surgical procedures. Rates of downstream interventions were considerably higher for women undergoing Pap smear follow-up (302 per 1000 with at least one downstream intervention), and surveillance of previous abnormalities (209 per 1000 with a downstream intervention).
Cervical cancer screening is widespread among elderly American women, and follow-up testing is not uncommon, particularly among the ten percent of women who appear to be in a cycle of repeated testing. This substantial volume of testing occurs despite the rarity of cervical cancer deaths and unknown benefits of screening in this age group.
尽管宫颈癌在65岁及以上女性中并非常见死因,但美国大多数老年女性报告仍在定期接受巴氏涂片筛查。
描述老年女性巴氏涂片及后续检查的发生率。
基于医疗保险索赔数据对65岁及以上女性医疗保险参保者进行分析。
利用三年的医疗保险B部分5%档案(1995 - 1997年),我们区分了接受筛查性巴氏涂片的女性和因监测既往异常或巴氏涂片后续检查而接受巴氏涂片的女性。我们确定了接受巴氏涂片检查的老年女性比例以及初次巴氏涂片后后续检查和手术的发生率。
1995年至1997年间,400万65岁以上的女性医疗保险受益人次接受了巴氏涂片检查,占符合条件人群的25%。在调整医疗保险下巴氏涂片计费不足的情况后,估计65岁以上女性中有43%在三年期间接受了巴氏涂片检查。绝大多数(90%)的巴氏涂片是用于筛查,而10%是用于监测或后续检查。每1000名接受筛查性巴氏涂片的女性中,有39人在初次巴氏涂片后的八个月内至少接受了一次后续干预,其中包括7名接受阴道镜检查的女性和2名接受其他外科手术的女性。对于接受巴氏涂片后续检查的女性(每1000人中有302人至少接受一次后续干预)和监测既往异常的女性(每1000人中有209人接受后续干预),后续干预的发生率要高得多。
宫颈癌筛查在美国老年女性中广泛存在,后续检查并不罕见,特别是在似乎处于重复检查周期的10%的女性中。尽管宫颈癌死亡罕见且该年龄组筛查的益处尚不清楚,但仍进行了大量的检查。